Role and mechanism of action of p62/Sqstm1 in Ras-induced tumorigenesis in lung
Role and mechanism of action of p62/Sqstm1 in Ras-induced tumorigenesis in lung
批准号:
8470563
负责人:
Jorge Moscat
金额:
$50.57万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-01 至 2015-05-31
关键词:
AblationAdenocarcinomaAffectAlveolarBindingCause of DeathCell Culture TechniquesCell SurvivalCellsCessation of lifeCritical PathwaysDependenceDevelopmentDisease ProgressionEmbryoEpithelial CellsFamilyFibroblastsGeneticGoalsHumanInflammatory ResponseIsoenzymesKnock-outKnowledgeLaboratoriesLeadLungLung AdenocarcinomaLung AdenomaLung NeoplasmsMAPK8 geneMalignant NeoplasmsMalignant neoplasm of lungMediator of activation proteinModelingMolecularMusMutateMutationNatureNeoplasmsNon-Small-Cell Lung CarcinomaOncogenicOrganPAWR genePathway interactionsPatientsPharmacotherapyPhosphotransferasesPlayProductionProteinsRas Signaling PathwayRegulationResearchRoleSamplingSignal PathwaySignal TransductionSignaling MoleculeSystemTestingUnited StatesWorkabstractingatypical protein kinase Ccancer cellcancer therapycancer typecell transformationdesignin vivoinhibitor/antagonistlung carcinogenesislung tumorigenesismetaplastic cell transformationmouse modelmutantnoveloverexpressionpreventras Oncogenetherapeutic targettumortumor progressiontumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Lung cancer is the leading cancer-related cause of death in the United States. Current treatments do not lead
to a cure for most patients with this type of neoplasia. Targeted anti-tumor therapies are likely to prove more
effective, but their development will require a better understanding of the signaling cascades involved. Ras
oncogenes are frequently mutated in human cancers where they play an unquestionably important role in the
genesis and progression of the disease. In lung adenocarcinomas, mutations in Ras are present in at least
25% of cases, suggesting that the components of Ras-related signaling pathways are promising candidates for
therapeutic targets in lung cancer treatment.
Ras oncogenic transformation activates NF-¿B, a critical regulator of cell survival and an essential
mediator of tumor progression. The atypical PKCs (aPKCs) and their adapter p62 are implicated in the control
of NF-¿B activation. Recent results demonstrate that genetic inactivation of the NF-¿B pathway may either
prevent or promote tumor development, depending on the target organ and whether or not the inflammatory
response is involved. However, the effect of NF-¿B inactivation in lung neoplasia has not yet been
documented. Preliminary studies demonstrate that Ras reproducibly produces lung adenomas and
adenocarcinomas in an inducible model of lung cancer in mice, and that p62 is required for these Ras-induced
lung tumors. The evidence suggests that this is a cell-autonomous effect in that the absence of p62 severely
impairs the ability of Ras to transform immortal embryo fibroblasts. In addition, Ras transformation induces p62
protein accumulation through a yet-to-be-defined mechanism. These important observations strongly indicate
that p62 is necessary for Ras-induced lung tumorigenesis and cell transformation.
The long-term goal of this project is to define novel signaling molecules that could be therapeutic
targets in lung cancer. The overall objective of this proposal is to rigorously test the hypothesis that the
p62/aPKC/NF-¿B pathway is critical in Ras-induced tumor transformation, specifically in lung cancer. This will
be achieved by assessing the roles and mechanism of action of these important signaling mediators in the
regulation of Ras-induced transformation. The specific aims designed to achieve this are to 1) Test the
hypothesis that p62 regulates Ras-induced lung cancer in vivo through the aPKCs; 2) Test the hypothesis that
IKK¿ or IKK¿ are critical mediators of Ras-induced formation of lung tumors; 3) Elucidate the cellular and
molecular mechanisms of the p62/aPKC/ NF-¿B pathway in Ras-induced transformation and its relevance in
human lung cancer. This work will increase our understanding of the mechanisms involved in the regulation of
lung cancer, and in the long term will provide the knowledge necessary for the development of novel, more
specific, and thus less toxic, therapies for this type of neoplasia.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1186/s40170-015-0128-2
发表时间:
2015
期刊:
Cancer & metabolism
影响因子:
5.9
作者:
[Ahn CS, Metallo CM]
通讯作者:
Metallo CM
Cholesterol metabolism in mesenchymal colorectal cancer
-
批准号:10557282
-
项目类别:
-
资助金额:$52.31万
-
财政年份:2022
-
负责人:Jorge Moscat
-
依托单位:
Molecular mechanisms driving mesenchymal colorectal cancer
-
批准号:10576886
-
项目类别:
-
资助金额:$44.81万
-
财政年份:2021
-
负责人:Jorge Moscat
-
依托单位:
Molecular mechanisms driving mesenchymal colorectal cancer
-
批准号:10374108
-
项目类别:
-
资助金额:$44.81万
-
财政年份:2021
-
负责人:Jorge Moscat
-
依托单位:
Interferon regulation by NBR1-driven chaperone-mediated autophagy in stellate cells in liver cancer
-
批准号:10533345
-
项目类别:
-
资助金额:$48.79万
-
财政年份:2021
-
负责人:Jorge Moscat
-
依托单位:
Mechanisms of cell death and autophagy in intestinal epithelial cells in inflammation and cancer
-
批准号:10180908
-
项目类别:
-
资助金额:$38.77万
-
财政年份:2017
-
负责人:Jorge Moscat
-
依托单位:
Control of stellate cells-driven liver cancer by the p62/NBR1 adapters
-
批准号:9891985
-
项目类别:
-
资助金额:$39.64万
-
财政年份:2016
-
负责人:Jorge Moscat
-
依托单位:
Protein Kinase Cz targets in Intestinal Cancer Stem Cells
-
批准号:8576130
-
项目类别:
-
资助金额:$44.55万
-
财政年份:2013
-
负责人:Jorge Moscat
-
依托单位:
Protein Kinase Cz targets in Intestinal Cancer Stem Cells
-
批准号:9054084
-
项目类别:
-
资助金额:$44.55万
-
财政年份:2013
-
负责人:Jorge Moscat
-
依托单位:
Protein Kinase Cz targets in Intestinal Cancer Stem Cells
-
批准号:8692683
-
项目类别:
-
资助金额:$43.22万
-
财政年份:2013
-
负责人:Jorge Moscat
-
依托单位:
Obesity-Induced Inflammation and Insulin Resistance by the p62/PKCzeta Signaling
-
批准号:8055418
-
项目类别:
-
资助金额:$41.08万
-
财政年份:2010
-
负责人:Jorge Moscat
-
依托单位:
Obesity-induced inflammation and insulin resistance by the p62/PKCzeta signaling
-
批准号:7863009
-
项目类别:
-
资助金额:$12.48万
-
财政年份:2010
-
负责人:Jorge Moscat
-
依托单位:
Obesity-Induced Inflammation and Insulin Resistance by the p62/PKCzeta Signaling
-
批准号:8258350
-
项目类别:
-
资助金额:$39.22万
-
财政年份:2010
-
负责人:Jorge Moscat
-
依托单位:
Obesity-Induced Inflammation and Insulin Resistance by the p62/PKCzeta Signaling
-
批准号:8235108
-
项目类别:
-
资助金额:$21.67万
-
财政年份:2010
-
负责人:Jorge Moscat
-
依托单位:
Role and mechanism of action of p62/Sqstm1 in Ras-induced tumorigenesis in lung
-
批准号:8079456
-
项目类别:
-
资助金额:$39.37万
-
财政年份:2009
-
负责人:Jorge Moscat
-
依托单位:
Role and mechanism of action of p62/Sqstm1 in Ras-induced tumorigenesis in lung
-
批准号:7904161
-
项目类别:
-
资助金额:$33.14万
-
财政年份:2009
-
负责人:Jorge Moscat
-
依托单位:
Role and mechanism of action of p62/Sqstm1 in Ras-induced tumorigenesis in lung
-
批准号:7729057
-
项目类别:
-
资助金额:$33.3万
-
财政年份:2009
-
负责人:Jorge Moscat
-
依托单位:
Role and mechanism of action of p62/Sqstm1 in Ras-induced tumorigenesis in lung
-
批准号:8277454
-
项目类别:
-
资助金额:$39.41万
-
财政年份:2009
-
负责人:Jorge Moscat
-
依托单位:
The p62/atypical PKC signaling complex in Th2 differentiation and asthma
-
批准号:7456694
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2008
-
负责人:Jorge Moscat
-
依托单位:
The p62/atypical PKC signaling complex in Th2 differentiation and asthma
-
批准号:7547763
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2008
-
负责人:Jorge Moscat
-
依托单位:
The p62/atypical PKC signaling complex in Th2 differentiation and asthma
-
批准号:7743107
-
项目类别:
-
资助金额:$38.61万
-
财政年份:2008
-
负责人:Jorge Moscat
-
依托单位:
国内基金
海外基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
-
批准号:30840003
-
项目类别:专项基金项目
-
资助金额:12.0万元
-
批准年份:2008
-
负责人:焦宇飞
-
依托单位: